Introduction
The relation between ventricular arrhythmias and death is not clear. Although they may constitute an independent risk factor for cardiac death, they may be simply markers of heart disease rather than causes of death. Certainly they are common in apparently healthy people.1 Ventricular arrhythmias occur frequently in the acute phase of myocardial infarction and their treatment is thought to reduce mortality,2 yet patients who have cardiac arrests do not exhibit more arrhythmias than those whose course appears to be uncomplicated.3 Similarly, the role in Immediate treatment with beta-blockers has been found both to reduce mortality,-and to have no effect.6 It has been claimed that any benefit they exert is by an antiarrhythmic action,'1 and also that their main function is to limit the size of the infarct.l1
We have used serial 24-hour electrocardiographic (ECG) recordings to investigate the incidence of arrhythmias during the six weeks after a suspected myocardial infarction and have assessed the effect on these arrhythmias of the beta-blockers propranolol and atenolol.
Patients and methods

PATIENTS
All the patients studied had been admitted to the coronary care units (CCUs) of Nottingham City Hospital and the General Hospital, Nottingham, within 24 hours after a suspected myocardial infarction. Provided they were free of haemodynamic complications (systolic blood pressure below 90 mm Hg, heart rate below 40 beats/min, moderate or severe heart failure, heart block), asthma, and diabetes they were entered on admission into a randomised double-blind trial comparing the effects of propranolol 40 mg thrice daily, atenolol 50 mg twice daily, and matching midday placebo or placebo tablets given thrice daily on morbidity and mortality during the first six weeks. Other antiarrhythmic agents were not given routinely.
On discharge from hospital the patients were assigned to one of the following diagnostic categories: (a) definite myocardial infarction-a convincing history with unequivocal changes in the ECG and serum enzyme concentrations; (b) probable infarction-a convincing history with either a classical ECG or classical changes in serum enzyme concentrations; (c) possible myocardial infarction-a convincing history and an abnormal ECG that was not classical of myocardial infarction, and an increase in serum enzyme concentrations to less than twice the upper limit of normal; (d) ischaemic heart diseasepatients with a history of myocardial infarction or angina whose ECGs were abnormal but in whom there were no ECG or enzyme changes to suggest a fresh event; and (e) chest pain ? cause-patients admitted with chest pain in whom no certain diagnosis was achieved. The categories "definite" and "probable" together corresponded to the WHO category of "definite infarction," and the other categories are included in the WHO category of "possible infarction." '2 The clinical results of the beta-blocker study will be described separately.
ECG TAPE-RECORDINGS
A total of 388 patients were admitted to the clinical study, and 24-hour ECG recordings were made on about a quarter of these, the patients being selected at random according to the availability of tape recorders and without knowledge of their treatment group or final diagnosis. Recordings were made within 24 hours after admission to the CCU, in a medical ward at least five days after admission, and at the outpatient clinic six weeks after admission. Some patients therefore underwent recording on more than one occasion.
Tape All intervals outside the range 333-2000 ms (heart rate 30-180 beats, min) were rejected as artefacts, and simple arithmetic procedures'4 were used to exclude the coupling interval and compensatory pause of ectopic beats. All other intervals were included in the determination of mean heart rate. Minimum and maximum heart rates were taken from five consecutive intervals, which did not vary by more than 5~o%. 519 when recordings were made who were receiving placebo, propranolol, or atenolol and the final diagnostic category in each treatment group.
The mean interval between the onset of symptoms and the beginning of recording in the CCU was 17 hours for patients receiving placebo and atenolol and 18 hours for patients receiving propranolol. The mean intervals between giving the first trial tablet and beginning the recording were 8, 11, and 10 hours respectively for patients taking placebo, propranolol, and atenolol. Two patients in each treatment group received lignocaine infusions at some stage during the recording, and two patients taking propranolol were given atropine; no other antiarrhythmic drugs were used while the recordings were being made. The mean interval between admission and recording in the medical ward was 7-0 days for patients given placebo, 6-5 days for those given propranolol, and 6-2 days for those given atenolol.
HEART RATES Table II shows the maximum, minimum, and mean heart rates recorded in each treatment group in the CCU, ward, and outpatient clinic. There was no significant difference between propranolol and atenolol, but both drugs significantly reduced the maximum heart rates when compared with placebo. Neither drug significantly affected the minimum heart rate. Eight patients taking placebo, but none taking a beta-blocker, had maximum heart rates recorded in the outpatient clinic exceeding 150 beats/min. In 27 patients (six taking placebo, nine propranolol, and 12 atenolol) minimum heart rates below 40 beats/min were recorded.
From these results we conclude that the patients taking betablockers were receiving a dose that was effective in reducing heart rate, and that in this respect at least propranolol and atenolol were equipotent in the doses used. Significance compared with placebo: *P-0-02; **P< 001; ***P <0001. Table III gives the numbers of patients in whom serious ventricular arrhythmias (couplets, ventricular tachycardia, and R-on-T ventricular extrasystoles) were recorded. Forty-two out of 55 patients (76%o) eventually shown to have had a definite or probable myocardial infarction had such arrhythmias in the CCU, but the incidence fell to 27% in the medical ward and 330% in outpatient clinic. Among patients not shown to have had a definite or probable infarction the incidences of serious arrhythmias were 24°o, 30%,, and 25°o on the three occasions when recordings were made. group, and 73°% in the atenolol group. The incidences of serious arrhythmias during the 48 hours of recording in patients monitored in both the medical ward and outpatient clinic were 50 %, 50°, and 53°% for placebo, propranolol, and atenolol respectively. Table VII gives the incidences of less serious ventricular arrhythmias. Only the reduced incidence of bigeminy associated with atenolol achieved statistical significance (P <002). Supraventricular ectopic beats were universal, and there was no difference in the incidence of supraventricular tachycardias between the treatment groups. Disorders of conduction were observed too rarely for useful analysis. It remains possible that it is the number of times that arrhythmias occur in a single patient, and not simply their presence, that confers risk. It is extremely difficult to compare groups of patients because of the wide variation between individual patients, but there was nothing in our results to suggest that arrhythmias that occur often and yet do not cause haemodynamic problems are any more dangerous than those that occur only occasionally.
INCIDENCE OF SERIOUS ARRHYTHMIAS
Although our patients were taking sufficient doses of propranolol and atenolol to reduce their maximum and mean heart rates, we found little evidence that these drugs had any useful antiarrhythmic action. Beta-blockers have antiarrhythmic properties when administered acutely, and in higher doses than we used they might have a prophylactic effect. A relatively high proportion of our patients, however, suffered sufficient hypotension to necessitate withdrawal from treatment, and we do not believe that in suspected acute myocardial infarction it is practicable routinely to give more than 40 mg propranolol thrice daily or 50 mg atenolol twice daily.
Even if beta-blockers have little antiarrhythmic effect in suspected myocardial infarction they may still reduce mortality by some other means. Beta-blockers are known, for example, to influence platelet behaviour18 and may limit infarct size.1' Our findings raise grave doubts about the value of studying arrhythmias to assess drugs intended to reduce mortality from myocardial infarction. Only clinical trials with death as an endpoint show the value of a drug; once a drug has been found to be effective then studies such as the one we have described may be needed to elucidate its mode of action. adolescents with convulsive disorders treated with phenytoin (n = 15) or phenobarbitone (n = 16) for over 12 months and in 27 age-matched healthy controls. The patients and controls ranged in age from 2 to 17 years. Neither patients nor controls had any malabsorption or
